Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Share-based Compensation (2020 - 2025)

Apellis Pharmaceuticals has reported Share-based Compensation over the past 6 years, most recently at $21.2 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $21.2 million for Q4 2025, down 19.26% from a year ago — trailing twelve months through Dec 2025 was $104.0 million (down 8.87% YoY), and the annual figure for FY2025 was $104.0 million, down 8.87%.
  • Share-based Compensation for Q4 2025 was $21.2 million at Apellis Pharmaceuticals, down from $28.2 million in the prior quarter.
  • Over the last five years, Share-based Compensation for APLS hit a ceiling of $30.3 million in Q1 2024 and a floor of $16.4 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $25.2 million (2022), compared with a mean of $24.3 million.
  • Biggest five-year swings in Share-based Compensation: surged 76.88% in 2021 and later fell 19.26% in 2025.
  • Apellis Pharmaceuticals' Share-based Compensation stood at $19.3 million in 2021, then grew by 25.52% to $24.2 million in 2022, then increased by 8.16% to $26.2 million in 2023, then increased by 0.36% to $26.3 million in 2024, then fell by 19.26% to $21.2 million in 2025.
  • The last three reported values for Share-based Compensation were $21.2 million (Q4 2025), $28.2 million (Q3 2025), and $27.2 million (Q2 2025) per Business Quant data.